A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
Clinical trial NCT05801029 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05801029
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-18
- Primary completion
- 2027-10-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.